Skip to Content


M. D. Anderson Rounding First Anniversary with SELECT Prostate Cancer Prevention Study


M. D. Anderson Rounding First Anniversary with SELECT Prostate Cancer Prevention Study
M. D. Anderson News Release 6/20/02

The University of Texas M. D. Anderson Cancer Center is celebrating the first anniversary of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) by hosting a pre-game dinner and free Astros game for all participants beginning at  6 p.m. Saturday, June 22, at Minute Maid Park.

More than 160 SELECT participants and their guests are expected to attend the event. 

The celebration begins with a pre-game dinner at Champions Pavilion of Minute Maid Park at  6 p.m., featuring classic ballpark fare. SELECT participants will sit together in Section 256, the area closest to Champions Pavilion, to watch the Houston Astros take on the Seattle Mariners.

National SELECT study coordinator Dr. Scott M. Lippman, chair of M. D. Anderson's Department of Clinical Cancer Prevention, will speak briefly at the dinner and will join the participants in Section 256 for the game.
"This event is our way of saying thank you to the men who have volunteered to take two pills daily for seven to 12 years," Dr. Lippman says. "Without their commitment to SELECT, we wouldn't be able to conduct this long-term clinical trial that may discover an effective means of preventing prostate cancer."

M. D. Anderson is one of more than 400 institutions throughout the United States, Canada and Puerto Rico recruiting volunteers to SELECT, the largest cancer prevention study ever conducted. M. D. Anderson has enrolled more than 150 men during the first year of a five-year recruitment period.

Participants take vitamin supplements and/or placebos daily for seven to 12 years, returning to M. D. Anderson every six months for follow-up visits.

The purpose of the study is to determine whether selenium and vitamin E can prevent prostate cancer, the third leading cancer killer in men. 

"We don't have all the answers now, but previous research has shown that these two minerals do provide some protection against prostate cancer," says Dr. Elise D. Cook, principal investigator of M. D. Anderson SELECT and assistant professor of clinical cancer prevention.

Despite progress in the early detection and treatment of the disease, about 198,000 men will be diagnosed with prostate cancer during 2002, according to the American Cancer Society. About 30,200 men are expected to die from the disease this year. African-American men are more likely to be diagnosed with prostate cancer and are twice as likely to die from the disease than men of any other racial or ethnic backgrounds.

"Given alarming statistics associated with prostate cancer, SELECT places a strong emphasis on recruiting African-Americans to participate, with a national recruitment goal of 6,500 black men," Dr. Cook says. "Locally, M. D. Anderson hopes to recruit 2,000 men, including 400 being African-American men."

Prospective SELECT participants must be healthy males who are at least 55 years old - 50 if African-American - and never diagnosed with prostate cancer.  Study volunteers will come to M. D. Anderson for follow-up examinations every six months and will be recommended to have an annual digital rectal exam and a prostate-specific antigen test. 

For more information, visit the SELECT website. Men interested in joining the study can call the "SELECT line" at M. D. Anderson at (713) 794-4400. Additional information is available from the National Cancer Institute's Cancer Information Service at 1-800-4-CANCER.  Both numbers offer information in English and Spanish.


© 2015 The University of Texas MD Anderson Cancer Center